Publications
- Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Physical Education and Sport
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Faculty of Medicine in Pilsen, Faculty of Science
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Faculty of Medicine in Pilsen
- The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy2013 | Faculty of Medicine in Pilsen
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Faculty of Medicine in Pilsen
- Polyneuropathic Pain Therapy with a Patient Suffering from Generalized Castrate Resistant Prostate Cancer - Clinical Case Report2013 | Faculty of Medicine in Pilsen
- Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer2012 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
Loading network view...
